Cyclarity reports safety data for atherosclerosis drug

Atherosclerosis is one of the leading causes of cardiovascular disease. In the fatty deposits (plaques) that form in blood vessels, a substance called 7-ketocholesterol (7KC) accumulates. This is an oxidized form of cholesterol that is toxic to cells and contributes to inflammation in the vessel wall.

Cyclarity Therapeutics uses a ring-shaped sugar molecule (cyclodextrin) that can encapsulate 7KC and carry it out of the body. The concept is not new: cyclodextrins are already used as excipients in drugs. Their specific application for 7KC in atherosclerosis is.

Phase 1: safety as the first step

A phase 1 study focuses primarily on safety, not efficacy. The study shows that the compound caused no serious adverse events in participants at the tested doses. That is a required first result, but says nothing yet about whether the drug actually reduces atherosclerosis.

The next question is whether lowering 7KC in the blood also leads to less plaque formation in the vessels, and ultimately to fewer heart attacks and strokes. Answering that requires larger, longer, and controlled studies.

7KC as an additional target

Current treatments for atherosclerosis focus mainly on lowering LDL cholesterol through statins. 7KC is a different target: it is not reduced by statins and is difficult to measure through standard blood tests. If 7KC does make a meaningful contribution to plaque formation and inflammation, an additional treatment strategy could complement existing therapies.

The therapy is still at an early stage. For patients with cardiovascular disease, this publication does not change treatment options in the short term.